CUE
Price:
$1.04
Market Cap:
$65.88M
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that foc...[Read more]
Industry
Biotechnology
IPO Date
2018-01-02
Stock Exchange
NASDAQ
Ticker
CUE
According to Cue Biopharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.14. This represents a change of -30.88% compared to the average of -1.65 of the last 4 quarters.
The mean historical PE Ratio of Cue Biopharma, Inc. over the last ten years is -22.05. The current -1.14 PE Ratio has changed 417.06% with respect to the historical average. Over the past ten years (40 quarters), CUE's PE Ratio was at its highest in in the September 2024 quarter at -1.12. The PE Ratio was at its lowest in in the September 2016 quarter at -29.65.
Average
-22.05
Median
-8.01
Minimum
-124.46
Maximum
-1.92
Discovering the peaks and valleys of Cue Biopharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 292.77%
Maximum Annual PE Ratio = -1.92
Minimum Annual Increase = -76.50%
Minimum Annual PE Ratio = -124.46
Year | PE Ratio | Change |
---|---|---|
2023 | -2.38 | 23.72% |
2022 | -1.92 | -75.98% |
2021 | -8.01 | -0.02% |
2020 | -8.01 | -15.95% |
2019 | -9.53 | 292.77% |
2018 | -2.43 | -76.50% |
2017 | -10.33 | -67.04% |
2016 | -31.35 | -74.82% |
The current PE Ratio of Cue Biopharma, Inc. (CUE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.11
5-year avg
-5.97
10-year avg
-22.05
Cue Biopharma, Inc.’s PE Ratio is greater than Coya Therapeutics, Inc. (-7.55), greater than Lantern Pharma Inc. (-1.70), greater than Fennec Pharmaceuticals Inc. (-140.94), less than Eliem Therapeutics, Inc. (0), greater than Anixa Biosciences, Inc. (-6.69), greater than INmune Bio, Inc. (-2.23), less than IN8bio, Inc. (-0.36), less than PolyPid Ltd. (-0.87), greater than X4 Pharmaceuticals, Inc. (-6.92), less than Galera Therapeutics, Inc. (-0.09), greater than Terns Pharmaceuticals, Inc. (-5.24), greater than Day One Biopharmaceuticals, Inc. (-14.55), less than HOOKIPA Pharma Inc. (-0.59), less than Cognition Therapeutics, Inc. (-0.72), less than TFF Pharmaceuticals, Inc. (-0.02), greater than TScan Therapeutics, Inc. (-3.21), less than Dermata Therapeutics, Inc. (-0.17),
Company | PE Ratio | Market cap |
---|---|---|
-7.55 | $88.72M | |
-1.70 | $32.57M | |
-140.94 | $170.33M | |
0 | $342.68M | |
-6.69 | $83.02M | |
-2.23 | $100.88M | |
-0.36 | $17.40M | |
-0.87 | $25.04M | |
-6.92 | $98.42M | |
-0.09 | $1.69M | |
-5.24 | $503.69M | |
-14.55 | $1.28B | |
-0.59 | $19.60M | |
-0.72 | $25.51M | |
-0.02 | $288.80K | |
-3.21 | $160.65M | |
-0.17 | $2.51M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cue Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cue Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cue Biopharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Cue Biopharma, Inc. (CUE)?
What is the highest PE Ratio for Cue Biopharma, Inc. (CUE)?
What is the 3-year average PE Ratio for Cue Biopharma, Inc. (CUE)?
What is the 5-year average PE Ratio for Cue Biopharma, Inc. (CUE)?
How does the current PE Ratio for Cue Biopharma, Inc. (CUE) compare to its historical average?